FOR ORPHAN DISEASE PATIENTS
Let's open up new markets and revenue streams by predicting more than one promising indication for a drug candidate at the early development stage.
We are a specialized discovery team with novel technologies and unique massive bio-pharmacological data resources for discovering hidden possibilities of drugs.
Two major causes of failure in clinical trials are lack of safety (~45% failure rate in Phase I) and efficacy (~65% failure rate in Phase II).
A synergistic drug combination increases the efficacy of the therapeutic effect and reduces toxicity as a result of decreased dosage.
Using our unique Multi-Strategy Drug Repositioning System, we will find the most synergistic drug partner that will target multiple pathological networks with your drug.
In the process of researching for orphan diseases, one may come across the problem of a lack of information.
That's where we step in. We can predict the pathological networks and suggest suitable drugs for diseases, on which you may have limited knowledge.
(16226) 경기도 수원시 영통구 대학4로 17 에이스광교 지식산업센터 1004-1호
(16226) ACE Gwanggyo Tower 1004-1Ho, 17, Daehak 4-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea
DR.NOAH BIOTECH on Facebook